Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Long-Term Investments (2019 - 2024)

Nurix Therapeutics (NRIX) has disclosed Long-Term Investments for 6 consecutive years, with $9.5 million as the latest value for Q3 2024.

  • Quarterly Long-Term Investments fell 4.15% to $9.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Aug 2024, down 4.15% year-over-year, with the annual reading at $7.4 million for FY2023, 88.38% down from the prior year.
  • Long-Term Investments for Q3 2024 was $9.5 million at Nurix Therapeutics, up from $9.4 million in the prior quarter.
  • The five-year high for Long-Term Investments was $137.2 million in Q4 2021, with the low at $7.4 million in Q4 2023.
  • Average Long-Term Investments over 5 years is $59.3 million, with a median of $51.5 million recorded in 2022.
  • The sharpest move saw Long-Term Investments surged 17862.45% in 2020, then crashed 88.38% in 2023.
  • Over 5 years, Long-Term Investments stood at $90.9 million in 2020, then skyrocketed by 50.94% to $137.2 million in 2021, then crashed by 53.44% to $63.9 million in 2022, then plummeted by 88.38% to $7.4 million in 2023, then rose by 27.64% to $9.5 million in 2024.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $9.5 million, $9.4 million, and $10.3 million for Q3 2024, Q2 2024, and Q1 2024 respectively.